Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02747043
Title Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE)
Acronym JASMINE
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Amgen
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ROU | POL | ITA | ISR | GRC | FRA | ESP | DEU | CZE | CAN | BGR | AUS


No variant requirements are available.